In Vitro Diagnostics

In Vitro Diagnostics (IVD) refers to medical devices used for testing human specimens (e.g., blood, urine, tissue) outside the body to provide clinical information. According to EU IVDR 2017/746 and Taiwan's Medical Device Act, IVDs are classified into four risk categories (A to D). Risk management is governed by ISO 14121 and ISO 14971, focusing on clinical performance and diagnostic accuracy. Unlike therapeutic devices, IVD risks center on misdiagnosis-induced harm, requiring rigorous validation of analytical sensitivity and specificity. Companies must ensure data---driven risk-adjusted-controls to be both EU and Taiwan compliant.

IVD risk management involves three stages: Risk-adjusted design (ISO 14971), Clinical Performance Evaluation (per EU IVDR Article 56), and Post-Market Surveillance (PMS). For example, a Taiwanese IVD firm implemented a real-time PMS dashboard, reducing adverse event reports by 35% within the first year. This quantitative improvement was achieved by integrating ISO 22301 Business Continuity Management with IVD-specific risk-adjusted controls. The key metric is the reduction in 'Risk-Adjusted Cost of Quality' (RACQ), which typically improves by 20-30% after standardizing the risk-adjusted control framework.

Taiwanese IVD enterprises face three primary challenges: Regulatory Complexity (transitioning from IVDD to IVDR), Data Privacy Compliance (GDPR and Taiwan PIPA), and Supply Chain Fragility. To overcome these, companies should: 1. Establish a dedicated Regulatory Affairs (RA) team within 30 days. 2. Implement ISO 27701 for data-centric compliance. 3. Diversify suppliers to mitigate geopolitical risks. Successful companies that prioritize these steps see a 50% reduction in regulatory delay and a significant improvement in investor confidence during due diligence processes.

Winners Consulting Services Co., Ltd. specializes in In Vitro Diagnostics for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact